4. (Amended) The method of claim 2, wherein said first molecule is selected from the group consisting of cDNA expression products, peptides, polypeptides, nucleic acids, lipids, sugars, steroids, and hybrids of said molecules and said second molecule is selected from the group consisting of cDNA expression products, peptides, polypeptides, and nucleic acids, lipids, sugars, steroids, and hybrids of said molecules.

5. The method of claim 4, wherein said cDNA expression product is an antibody or a fragment or a derivative thereof, an enzyme or a fragment thereof, a surface protein or a fragment thereof, or a nucleic acid-binding protein or a fragment thereof.

6. (Amended) The method of claim 1, wherein said first molecule is a peptide or polypetide presented on the surface of organisms and/or organelles and/or soluble molecules and wherein the method further comprises after step (b) and prior to step (c) the step of:

(b') amplifying a peptide or polypetide specifically interacting with said second molecule,

wherein step (b') is carried out in one or more containers preferably representing an arrayed form.

7. The method of claim 6, wherein prior to step (a) said library of first molecules (library 1) is preabsorbed with unloaded magnetic particles and/or molecules competitive (cross-reactive) to second molecules (target, library 2).

8. The method of claim 6 or 7 which further comprises after step (c) and prior to step (d) the step of:

(c') repeating steps (a), (b) and (c) and, optionally, step (b') at least once.

9. The method of claim 8, wherein steps (c) and (c') are performed in parallel.

10. (Amended) The method of claim 1, wherein said number of specifically interacting molecules is a pair of interacting molecules.

11. (Amen[redacted] The method of claim 1, wherein said n[redacted]ber of specifically interacting molecules are three or more interacting molecules.

12. (Amended) The method of claim 1, further comprising the step of characterizing said first and/or second molecule and/or the corresponding genetic information.

13. (Amended) The method of claim 1, wherein said second molecule target is affixed to said magnetic particle via an affinity tag and/or unspecific adsorption and/or covalent binding.

14. The method of claim 13, wherein said metal-chelating tag is a His-tag, and/or said epitope tag is an HA-tag, a c-myc-tag, a VSV-G-tag, an α-tubulin-tag, a B-tag, an E-tag, FLAG, a His-tag, an HSV-tag, a Pk-tag, a protein C-tag, a T7-tag, EpiTag™, a V5-tag or an S-tag, and/or said enzyme binding domain is cellulose binding domain, barnase or maltose binding protein.

15. (Amended) The method of claim 1, wherein step (c) is effected by immunological means.

16. The method of claim 15, wherein step (c) is effected by ELISA, RIA, western/colony blotting, FACS or immunohistochemistry.

17. The method of claim 15 or 16, wherein step (c) is effected in (micro-)array format, preferably on a membrane and/or filter and/or a glas slide and/or in a microtiter plate.

18. A method for the production of a pharmaceutical composition comprising the steps of the method of claim 1 and further the step of formulating said first and/or second molecule selected and/or characterized by the method of claim 1 or a functionally and/or structurally equivalent derivative thereof in a pharmaceutically acceptable form.

19. (New) The method of claim 1, wherein said one or more containers comprise one or more microtiter plates.

20. (New) The method of claim 6, wherein said one or more containers comprise one or more microtiter plates.